Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2011, Article ID 376509, 11 pages
http://dx.doi.org/10.1155/2011/376509
Review Article

Activation of the GLP-1 Receptor Signalling Pathway: A Relevant Strategy to Repair a Deficient Beta-Cell Mass

Laboratoire B2PE (Biologie et Pathologie du Pancréas Endocrine), Unité BFA (Biologie Fonctionnelle et Adaptive), Equipe 1, Université Paris-Diderot et CNRS EAC 4413, Bâtiment BUFFON, 5ème étage, pièce 552A, 4, Rue Lagroua Weill Hallé, Case 7126, 75205 Paris Cedex 13, France

Received 30 December 2010; Accepted 25 February 2011

Academic Editor: Matteo Monami

Copyright © 2011 Bernard Portha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R. A. Rizza, and P. C. Butler, “β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes,” Diabetes, vol. 52, no. 1, pp. 102–110, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. R. P. Robertson, “Successful islet transplantation for patients with diabetes—fact or fantasy?” The New England Journal of Medicine, vol. 343, no. 4, pp. 289–290, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Salehi, B. A. Aulinger, and D. A. D'Alessio, “Targeting β-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins,” Endocrine Reviews, vol. 29, no. 3, pp. 367–379, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. J. J. Meier, A. E. Butler, R. Galasso, R. A. Rizza, and P. C. Butler, “Increased islet beta cell replication adjacent to intrapancreatic gastrinomas in humans,” Diabetologia, vol. 49, no. 11, pp. 2689–2696, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. J. J. Meier, J. C. Lin, A. E. Butler, R. Galasso, D. S. Martinez, and P. C. Butler, “Direct evidence of attempted beta cell regeneration in an 89-year-old patient with recent-onset type 1 diabetes,” Diabetologia, vol. 49, no. 8, pp. 1838–1844, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Tillmar, C. Carlsson, and N. Welsh, “Control of insulin mRNA stability in rat pancreatic islets: regulatory role of a 3-untranslated region pyrimidine-rich sequence,” Journal of Biological Chemistry, vol. 277, no. 2, pp. 1099–1106, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. K. P. Knoch, R. Meisterfeld, S. Kersting et al., “cAMP-dependent phosphorylation of PTB1 promotes the expression of insulin secretory granule proteins in β cells,” Cell Metabolism, vol. 3, no. 2, pp. 123–134, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. D. J. Drucker, J. Philippe, S. Mojsov, W. L. Chick, and J. F. Habener, “Glucagon-like peptide 1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line,” Proceedings of the National Academy of Sciences USA, vol. 84, pp. 3434–3438, 1987. View at Google Scholar
  9. X. Wang, C. M. Cahill, M. A. Pineyro, J. Zhou, M. E. Doyle, and J. M. Egan, “Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells,” Endocrinology, vol. 140, no. 10, pp. 4904–4907, 1999. View at Google Scholar · View at Scopus
  10. X. Wang, J. Zhou, M. E. Doyle, and J. M. Egan, “Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic β-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism,” Endocrinology, vol. 142, no. 5, pp. 1820–1827, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. D. A. Stoffers, T. J. Kieffer, M. A. Hussain et al., “Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas,” Diabetes, vol. 49, no. 5, pp. 741–748, 2000. View at Google Scholar · View at Scopus
  12. H. Ohlsson, K. Karlsson, and T. Edlund, “IPF1, a homeodomain-containing transactivator of the insulin gene,” The EMBO Journal, vol. 12, no. 11, pp. 4251–4259, 1993. View at Google Scholar
  13. J. Le Lay and R. Stein, “Involvement of PDX-1 in activation of human insulin gene transcription,” Journal of Endocrinology, vol. 188, no. 2, pp. 287–294, 2006. View at Publisher · View at Google Scholar
  14. T. Kitamura, J. Nakae, Y. Kitamura et al., “The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic β cell growth,” Journal of Clinical Investigation, vol. 110, no. 12, pp. 1839–1847, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Buteau, M. L. Spatz, and D. Accili, “Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β-cell mass,” Diabetes, vol. 55, no. 5, pp. 1190–1196, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Skoglund, M. A. Hussain, and G. G. Holz, “Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element,” Diabetes, vol. 49, no. 7, pp. 1156–1164, 2000. View at Google Scholar · View at Scopus
  17. O. G. Chepurny, M. A. Hussain, and G. G. Holz, “Exendin-4 as a stimulator of rat insulin I gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31-8220,” Endocrinology, vol. 143, no. 6, pp. 2303–2313, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. P. E. Light, J. E. Manning Fox, M. J. Riedel, and M. B. Wheeler, “Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism,” Molecular Endocrinology, vol. 16, no. 9, pp. 2135–2144, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Gromada, J. J. Holst, and P. Rorsman, “Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1,” Pflugers Archiv European Journal of Physiology, vol. 435, no. 5, pp. 583–594, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Nakazaki, A. Crane, M. Hu et al., “cAMP-activated protein kinase-independent potentiation of insulin secretion by cAMP is impaired in SUR1 null islets,” Diabetes, vol. 51, no. 12, pp. 3440–3449, 2002. View at Google Scholar · View at Scopus
  21. C. Shiota, O. Larsson, K. D. Shelton et al., “Sulfonylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose,” Journal of Biological Chemistry, vol. 277, no. 40, pp. 37176–37183, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. J. De Rooij, F. J. T. Zwartkruis, M. H. G. Verheijen et al., “Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP,” Nature, vol. 396, no. 6710, pp. 474–477, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Kawasaki, G. M. Springett, N. Mochizuki et al., “A family of cAMP-binding proteins that directly activate Rap1,” Science, vol. 282, no. 5397, pp. 2275–2279, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Shibasaki, Y. Sunaga, and S. Seino, “Integration of ATP, cAMP, and Ca2+ signals in insulin granule exocytosis,” Diabetes, vol. 53, no. 3, pp. S59–S62, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Kang, O. G. Chepurny, B. Malester et al., “cAMP sensor Epac as a determinant of ATP-sensitive potassium channel activity in human pancreatic β cells and rat INS-1 cells,” Journal of Physiology, vol. 573, no. 3, pp. 595–609, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Sonoda, T. Imamura, T. Yoshizaki, J. L. Babendure, J. C. Lu, and J. M. Olefsky, “β-arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic β cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 18, pp. 6614–6619, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. P. E. MacDonald, X. Wang, F. Xia et al., “Antagonism of rat β-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways,” Journal of Biological Chemistry, vol. 278, no. 52, pp. 52446–52453, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. L. B. Lester, L. K. Langeberg, and J. D. Scott, “Anchoring of protein kinase A facilitates hormone-mediated insulin secretion,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 26, pp. 14942–14947, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. L. D. C. Fraser, S. J. Tavalin, L. B. Lester et al., “A novel lipid-anchored A-kinase anchoring protein facilitates cAMP-responsive membrane events,” The EMBO Journal, vol. 17, no. 8, pp. 2261–2272, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. J. T. Hulme, T. W. C. Lin, R. E. Westenbroek, T. Scheuer, and W. A. Catterall, “β-adrenergic regulation requires direct anchoring of PKA to cardiac Ca1.2 channels via a leucine zipper interaction with A kinase-anchoring protein 15,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 22, pp. 13093–13098, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Kang, J. W. Joseph, O. G. Chepurny et al., “Epac-selective cAMP analog 8-pCPT-2-O-Me-cAMP as a stimulus for Ca2+-induced Ca2+ release and exocytosis in pancreatic β-cells,” Journal of Biological Chemistry, vol. 278, no. 10, pp. 8279–8285, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Tsuboi, G. da Silva Xavier, G. G. Holz, L. S. Jouaville, A. P. Thomas, and G. A. Rutter, “Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 β-cells,” Biochemical Journal, vol. 369, no. 2, pp. 287–299, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. B. J. Kim, K. H. Park, C. Y. Yim et al., “Generation of nicotinic acid adenine dinucleotide phosphate and cyclic ADP-ribose by glucagon-like peptide-1 evokes Ca2+ signal that is essential for insulin secretion in mouse pancreatic islets,” Diabetes, vol. 57, no. 4, pp. 868–878, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. I. Kato, Y. Yamamoto, M. Fujimura, N. Noguchi, S. Takasawa, and H. Okamoto, “CD38 disruption impairs glucose-induced increases in cyclic ADP-ribose, [Ca2+]i, and insulin secretion,” Journal of Biological Chemistry, vol. 274, no. 4, pp. 1869–1872, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. L. B. Lester, M. C. Faux, J. B. Nauert, and J. D. Scott, “Targeted protein kinase A and PP-2B regulate insulin secretion through reversible phosphorylation,” Endocrinology, vol. 142, no. 3, pp. 1218–1227, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Lonart, S. Schoch, P. S. Kaeser, C. J. Larkin, T. C. Südhof, and D. J. Linden, “Phosphorylation of RIM1α by PKA triggers presynaptic long-term potentiation at cerebellar parallel fiber synapses,” Cell, vol. 115, no. 1, pp. 49–60, 2003. View at Publisher · View at Google Scholar
  37. Y. Wang, M. Okamoto, F. Schmitz, K. Hofmann, and T. C. Südhof, “Rim is a putative rab3 effector in regulating synaptic-vesicle fusion,” Nature, vol. 388, no. 6642, pp. 593–598, 1997. View at Publisher · View at Google Scholar
  38. A. Betz, P. Thakur, H. J. Junge et al., “Functional interaction of the active zone proteins Munc13-1 and RIM1 in synaptic vesicle priming,” Neuron, vol. 30, no. 1, pp. 183–196, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. N. Ozaki, T. Shibasaki, Y. Kashima et al., “cAMP-GEFII is a direct target of cAMP in regulated exocytosis,” Nature Cell Biology, vol. 2, no. 11, pp. 805–811, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. E. P. Kwan, L. Xie, L. Sheu, T. Ohtsuka, and H. Y. Gaisano, “Interaction between Munc13-1 and RIM is critical for glucagon-like peptide-1-mediated rescue of exocytotic defects in Munc13-1-deficient pancreatic β-cells,” Diabetes, vol. 56, no. 10, pp. 2579–2588, 2007. View at Publisher · View at Google Scholar
  41. K. Fujimoto, T. Shibasaki, N. Yokoi et al., “Piccolo, a Ca2+ sensor in pancreatic β-cells: involvement of cAMP-GEFII·Rim2·Piccolo complex in cAMP-dependent exocytosis,” Journal of Biological Chemistry, vol. 277, no. 52, pp. 50497–50502, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. D. G. Pipeleers, F. C. Schuit, and P. A. In't Veld, “Interplay of nutrients and hormones in the regulation of insulin release,” Endocrinology, vol. 117, no. 3, pp. 824–833, 1985. View at Google Scholar
  43. M. Cornu, H. Modi, D. Kawamori, R. N. Kulkarni, M. Joffraud, and B. Thorens, “Glucagon-like peptide-1 increases β-cell glucose competence and proliferation by translational induction of insulin-like growth factor-1 receptor expression,” Journal of Biological Chemistry, vol. 285, no. 14, pp. 10538–10545, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. G. G. Holz, W. M. Kuhtreiber, and J. F. Habener, “Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7–37),” Nature, vol. 361, no. 6410, pp. 362–365, 1993. View at Publisher · View at Google Scholar · View at Scopus
  45. M.-L. Peyot, J. P. Gray, J. Lamontagne et al., “Glucagon-like peptide-1 induced signaling and insulin secretion do not drive fuel and energy metabolism in primary rodent pancreatic β-cells,” PLoS One, vol. 4, no. 7, Article ID e6221, 2009. View at Publisher · View at Google Scholar
  46. B. Portha, G. Lacraz, M. Kergoat et al., “The GK rat beta-cell: a prototype for the diseased human beta-cell in type 2 diabetes?” Molecular and Cellular Endocrinology, vol. 297, no. 1-2, pp. 73–85, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Dolz, J. Movassat, M. Fradet et al., “cAMP-secretion coupling is impaired in the diabetic GK/par beta-cells. A defect counteracted by GLP-1,” submitted.
  48. N. Dachicourt, P. Serradas, D. Bailbé, M. Kergoat, L. Doaré, and B. Portha, “Glucagon-like peptide-1(7–36)-amide confers glucose sensitivity to previously glucose-incompetent β-cells in diabetic rats: in vivo and in vitro studies,” Journal of Endocrinology, vol. 155, no. 2, pp. 369–376, 1997. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Buteau, S. Foisy, E. Joly, and M. Prentki, “Glucagon-like peptide 1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor,” Diabetes, vol. 52, no. 1, pp. 124–132, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. D. J. Drucker, “Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis,” Molecular Endocrinology, vol. 17, no. 2, pp. 161–171, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Li, X. Cao, L. X. Li, P. L. Brubaker, H. Edlund, and D. J. Drucker, “β-cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1,” Diabetes, vol. 54, no. 2, pp. 482–491, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Trümper, K. Trümper, and D. Hörsch, “Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in β(INS-1)-cells,” Journal of Endocrinology, vol. 174, no. 2, pp. 233–246, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Buteau, S. Foisy, C. J. Rhodes, L. Carpenter, T. J. Biden, and M. Prentki, “Protein kinase Cζ activation mediates glucagon-like peptide-1—induced pancreatic β-cell proliferation,” Diabetes, vol. 50, no. 10, pp. 2237–2243, 2001. View at Google Scholar · View at Scopus
  54. J. Buteau, R. Roduit, S. Susini, and M. Prentki, “Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells,” Diabetologia, vol. 42, no. 7, pp. 856–864, 1999. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Demeterco, G. M. Beattie, S. A. Dib, A. D. Lopez, and A. Hayek, “A role for activin A and betacellulin in human fetal pancreatic cell differentiation and growth,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 10, pp. 3892–3897, 2000. View at Google Scholar · View at Scopus
  56. J. Movassat, G. M. Beattie, A. D. Lopez, and A. Hayek, “Exendin 4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 10, pp. 4775–4781, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. T. Xie, M. Chen, Q.-H. Zhang, Z. Ma, and L. S. Weinstein, “β cell-specific deficiency of the stimulatory G protein α-subunit Gsα leads to reduced β cell mass and insulin-deficient diabetes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 49, pp. 19601–19606, 2007. View at Publisher · View at Google Scholar
  58. U. S. Jhala, G. Canettieri, R. A. Screaton et al., “cAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2,” Genes and Development, vol. 17, no. 13, pp. 1575–1580, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. B. N. Friedrichsen, N. Neubauer, Y. C. Lee et al., “Stimulation of pancreatic β-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways,” Journal of Endocrinology, vol. 188, no. 3, pp. 481–492, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. M.-J. Kim, J.-H. Kang, Y. G. Park et al., “Exendin-4 induction of cyclin D1 expression in INS-1 β-cells: involvement of cAMP-responsive element,” Journal of Endocrinology, vol. 188, no. 3, pp. 623–633, 2006. View at Publisher · View at Google Scholar
  61. R. Lupi, R. Mancarella, S. Del Guerra et al., “Effects of exendin-4 on islets from type 2 diabetes patients,” Diabetes, Obesity and Metabolism, vol. 10, no. 6, pp. 515–519, 2008. View at Publisher · View at Google Scholar
  62. Z. Liu and J. F. Habener, “Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation,” Journal of Biological Chemistry, vol. 283, no. 13, pp. 8723–8735, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. K. Tanabe, Z. Liu, S. Patel et al., “Genetic deficiency of glycogen synthase kinase-3beta corrects diabetes in mouse models of insulin resistance.,” PLoS Biology, vol. 6, no. 2, article e37, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. F. Figeac, B. Uzan, M. Faro, N. Chelali, B. Portha, and J. Movassat, “Neonatal growth and regeneration of β-cells are regulated by the Wnt/β-catenin signaling in normal and diabetic rats,” American Journal of Physiology, vol. 298, no. 2, pp. E245–E256, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. L. Farilla, H. Hongxiang, C. Bertolotto et al., “Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats,” Endocrinology, vol. 143, no. 11, pp. 4397–4408, 2002. View at Publisher · View at Google Scholar · View at Scopus
  66. W. Kim and J. M. Egan, “The role of incretins in glucose homeostasis and diabetes treatment,” Pharmacological Reviews, vol. 60, no. 4, pp. 470–512, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. Li, T. Hansotia, B. Yusta, F. Ris, P. A. Halban, and D. J. Drueker, “Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis,” Journal of Biological Chemistry, vol. 278, no. 1, pp. 471–478, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. B. Yusta, L. L. Baggio, J. L. Estall et al., “GLP-1 receptor activation improves β cell function and survival following induction of endoplasmic reticulum stress,” Cell Metabolism, vol. 4, no. 5, pp. 391–406, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Tsunekawa, N. Yamamoto, K. Tsukamoto et al., “Protection of pancreatic β-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies,” Journal of Endocrinology, vol. 193, no. 1, pp. 65–74, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. J. Buteau, W. El-Assaad, C. J. Rhodes, L. Mosenberg, E. Joly, and M. Prentki, “Glucagon-like peptide-1 prevents beta cell glucolipotoxicity,” Diabetologia, vol. 47, no. 5, pp. 806–815, 2004. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Ferdaoussi, S. Abdelli, J. Y. Yang et al., “Exendin-4 protects β-cells from interleukin-1β-induced apoptosis by interfering with the c-Jun NH-terminal kinase pathway,” Diabetes, vol. 57, no. 5, pp. 1205–1215, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Blandino-Rosano, G. Perez-Arana, J. M. Mellado-Gil, C. Segundo, and M. Aguilar-Diosdado, “Anti-proliferative effect of pro-inflammatory cytokines in cultured β cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide -1,” Journal of Molecular Endocrinology, vol. 41, no. 1-2, pp. 35–44, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. D. Tornehave, P. Kristensen, J. Rømer, L. B. Knudsen, and R. S. Heller, “Expression of the GLP-1 receptor in mouse, rat, and human pancreas,” Journal of Histochemistry and Cytochemistry, vol. 56, no. 9, pp. 841–851, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. G. Xu, H. Kaneto, M. D. Lopez-Avalos, G. C. Weir, and S. Bonner-Weir, “GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts,” Diabetes Research and Clinical Practice, vol. 73, no. 1, pp. 107–110, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. J. Zhou, C. Montrose-Rafizadeh, A. M. Janczewski et al., “Glucagon-like peptide-1 does not mediate amylase release from AR42J cells,” Journal of Cellular Physiology, vol. 181, no. 3, pp. 470–478, 1999. View at Publisher · View at Google Scholar · View at Scopus
  76. J. Zhou, X. Wang, M. A. Pineyro, and J. M. Egan, “Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells,” Diabetes, vol. 48, no. 12, pp. 2358–2366, 1999. View at Google Scholar · View at Scopus
  77. K. H. Yew, M. Hembree, K. Prasadan et al., “Cross-talk between bone morphogenetic protein and transforming growth factor-β signaling is essential for exendin-4-induced insulin-positive differentiation of AR42J cells,” Journal of Biological Chemistry, vol. 280, no. 37, pp. 32209–32217, 2005. View at Publisher · View at Google Scholar · View at Scopus
  78. E. Tei, S. Mehta, S. S. Tulachan et al., “Synergistic endocrine induction by GLP-1 and TGF-β in the developing pancreas,” Pancreas, vol. 31, no. 2, pp. 138–141, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. H. Mashima, H. Ohnishi, K. Wakabayashi et al., “Betacellulin and activin A coordinately convert amylase-secreting pancreatic AR42J cells into insulin-secreting cells,” Journal of Clinical Investigation, vol. 97, no. 7, pp. 1647–1654, 1996. View at Google Scholar · View at Scopus
  80. J. Zhou, M. A. Pineyro, X. Wang, M. E. Doyle, and J. M. Egan, “Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3β transcription factors,” Journal of Cellular Physiology, vol. 192, no. 3, pp. 304–314, 2002. View at Publisher · View at Google Scholar · View at Scopus
  81. H. Hui, C. Wright, and R. Perfetti, “Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells,” Diabetes, vol. 50, no. 4, pp. 785–796, 2001. View at Google Scholar · View at Scopus
  82. B. Rolin, M. O. Larsen, C. F. Gotfredsen et al., “The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice,” American Journal of Physiology, vol. 283, no. 4, pp. E745–E752, 2002. View at Google Scholar · View at Scopus
  83. C. Tourrel, D. Bailbé, M. J. Meile, M. Kergoat, and B. Portha, “Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age,” Diabetes, vol. 50, no. 7, pp. 1562–1570, 2001. View at Google Scholar · View at Scopus
  84. C. Tourrel, D. Bailbe, M. Lacorne, M.-J. Meile, M. Kergoat, and B. Portha, “Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4,” Diabetes, vol. 51, no. 5, pp. 1443–1452, 2002. View at Google Scholar
  85. Q. Wang and P. Brubaker, “Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice,” Diabetologia, vol. 45, no. 9, pp. 1263–1273, 2002. View at Publisher · View at Google Scholar
  86. G. Xu, D. A. Stoffers, J. F. Habener, and S. Bonner-Weir, “Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats,” Diabetes, vol. 48, no. 12, pp. 2270–2276, 1999. View at Google Scholar · View at Scopus
  87. D. A. Stoffers, B. M. Desai, D. D. DeLeon, and R. A. Simmons, “Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat,” Diabetes, vol. 52, no. 3, pp. 734–740, 2003. View at Publisher · View at Google Scholar · View at Scopus
  88. J. M. Egan, A. Bulotta, H. Hui, and R. Perfetti, “GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells,” Diabetes/Metabolism Research and Reviews, vol. 19, no. 2, pp. 115–123, 2003. View at Publisher · View at Google Scholar · View at Scopus
  89. S. Klinger, C. Poussin, M. B. Debril, W. Dolci, P. A. Halban, and B. Thorens, “Increasing GLP-1-induced β-cell proliferation by silencing the negative regulators of signaling cAMP response element modulator-α and DUSP14,” Diabetes, vol. 57, no. 3, pp. 584–593, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. S. R. Ahmad and J. Swann, “Exenatide and rare adverse events,” The New England Journal of Medicine, vol. 358, no. 18, pp. 1970–1971, 2008. View at Google Scholar · View at Scopus
  91. J. A. Koehler, L. L. Baggio, B. J. Lamont, S. Ali, and D. J. Drucker, “Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice,” Diabetes, vol. 58, no. 9, pp. 2148–2161, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. D. D. Dore, J. D. Seeger, and K. A. Chan, “Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide,” Current Medical Research and Opinion, vol. 25, no. 4, pp. 1019–1027, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. A. V. Matveyenko, S. Dry, H. I. Cox et al., “Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin,” Diabetes, vol. 58, no. 7, pp. 1604–1615, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. J. S. Nachnani, D. G. Bulchandani, A. Nookala et al., “Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas,” Diabetologia, vol. 53, no. 1, pp. 153–159, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. A. E. Butler, R. Galasso, A. Matveyenko, R. A. Rizza, S. Dry, and P. C. Butler, “Pancreatic duct replication is increased with obesity and type 2 diabetes in humans,” Diabetologia, vol. 53, no. 1, pp. 21–26, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. M. Y. Donath, D. M. Schumann, M. Faulenbach, H. Ellingsgaard, A. Perren, and J. A. Ehses, “Islet inflammation in type 2 diabetes: from metabolic stress to therapy,” Diabetes care, vol. 31, supplement 2, pp. S161–S164, 2008. View at Google Scholar · View at Scopus
  97. J. Zhang, Y. Tokui, K. Yamagata et al., “Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes,” Diabetologia, vol. 50, no. 9, pp. 1900–1909, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. Z. Yang, M. Chen, J. D. Carter et al., “Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes,” Biochemical and Biophysical Research Communications, vol. 344, no. 3, pp. 1017–1022, 2006. View at Publisher · View at Google Scholar · View at Scopus
  99. N. Ogawa, J. F. List, J. F. Habener, and T. Maki, “Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4,” Diabetes, vol. 53, no. 7, pp. 1700–1705, 2004. View at Publisher · View at Google Scholar · View at Scopus
  100. N. A. Sherry, W. Chen, J. A. Kushner et al., “Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of β-cells,” Endocrinology, vol. 148, no. 11, pp. 5136–5144, 2007. View at Publisher · View at Google Scholar
  101. S. J. Kim, C. Nian, D. J. Doudet, and C. H. S. Mcintosh, “Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation,” Diabetes, vol. 58, no. 3, pp. 641–651, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. U. Pugazhenthi, K. Velmurugan, A. Tran, G. Mahaffey, and S. Pugazhenthi, “Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients,” Diabetologia, vol. 53, no. 11, pp. 2357–2368, 2010. View at Publisher · View at Google Scholar
  103. G. Pérez-Arana, M. Blandino-Rosano, A. Prada-Oliveira, M. Aguilar-Diosdado, and C. Segundo, “Decrease in β-cell proliferation precedes apoptosis during diabetes development in bio-breeding/worcester rat: beneficial role of exendin-4,” Endocrinology, vol. 151, no. 6, pp. 2538–2546, 2010. View at Publisher · View at Google Scholar
  104. P. L. Brubaker and D. J. Drucker, “Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system,” Endocrinology, vol. 145, no. 6, pp. 2653–2659, 2004. View at Publisher · View at Google Scholar · View at Scopus
  105. S. Thyssen, E. Arany, and D. J. Hill, “Ontogeny of regeneration of β-cells in the neonatal rat after treatment with streptozotocin,” Endocrinology, vol. 147, no. 5, pp. 2346–2356, 2006. View at Publisher · View at Google Scholar
  106. Y. Nie, M. Nakashima, P. L. Brubaker et al., “Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats,” Journal of Clinical Investigation, vol. 105, no. 7, pp. 955–965, 2000. View at Google Scholar · View at Scopus
  107. R. D. Wideman, I. L. Y. Yu, T. D. Webber et al., “Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1),” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 36, pp. 13468–13473, 2006. View at Publisher · View at Google Scholar · View at Scopus
  108. R. D. Wideman, S. D. Covey, G. C. Webb, D. J. Drucker, and T. J. Kieffer, “A switch from prohormone convertase (PC)-2 to PC1/3 expression in transplanted α-cells is accompanied by differential processing of proglucagon and improved glucose homeostasis in mice,” Diabetes, vol. 56, no. 11, pp. 2744–2752, 2007. View at Publisher · View at Google Scholar